Salix Coronary Plaque vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, Salix Coronary Plaque, is designed for the assessment of coronary artery disease by analyzing CCTA scans for plaque and stenosis. Tool B, EchoGo Amyloidosis, focuses on the early detection of cardiac amyloidosis through the analysis of echocardiogram video clips. While both are AI-powered cardiology tools, they target different cardiac conditions and utilize distinct imaging modalities, making them complementary rather than directly competitive.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Artrya Salix Coronary Plaque is designed to aid in the rapid and accurate diagnosis of coronary artery disease by assessing coronary artery plaque and stenosis from CCTA scans. Ultromics EchoGo Amyloidosis is an AI-powered screening tool for the early detection of cardiac amyloidosis from echocardiogram video clips.
Artrya Salix Coronary Plaque analyzes CCTA (Coronary CT Angiography) scans. Ultromics EchoGo Amyloidosis analyzes echocardiogram video clips, specifically requiring a single apical four-chamber image.
Artrya Salix Coronary Plaque provides detection and quantification of coronary plaque, identification of high-risk plaque features, stenosis assessment, and quantification of calcifications (calcium scoring), with automated report generation. Ultromics EchoGo Amyloidosis identifies suspected cardiac amyloidosis and provides a diagnostic output of 'suggestive' or 'not suggestive' of the condition, based on the analysis of echocardiographic markers.
Artrya Salix Coronary Plaque operates on a per-scan assessment model with a US CPT reimbursement rate of US$950 per assessment. Ultromics EchoGo Amyloidosis has an NTAP Code ICD-10 XXE2X19 for inpatient analysis at $1,000 per analysis and a HCPCS Code C9786 (Clinical APC Code 574) for outpatient analysis at $285 per analysis, both covered by Medicare and select commercial insurers.
Artrya Salix Coronary Plaque is stated to aid in rapid and accurate diagnosis of coronary artery disease, but specific sensitivity and specificity metrics are not explicitly detailed in the provided information. Ultromics EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity, demonstrating consistent performance across cardiac amyloidosis subtypes.
Artrya Salix Coronary Plaque features integrated workflow management and automated, editable report generation, designed for near real-time, point-of-care assessment from CCTA scans. Ultromics EchoGo Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, operating as a cloud-based SaaS model.
Artrya Salix Coronary Plaque is designed for use by specialists in Cardiology and Radiology. Ultromics EchoGo Amyloidosis is primarily designed to support Cardiology specialists.